Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro

Morokutti-Kurz et al., PLoS ONE, doi:10.1371/journal.pone.0237480

Feb 2021

Source PDF All Studies Meta AnalysisMeta

In Vitro study showing that SARS-CoV-2 is inhibited by iota-carrageenan in a dose dependent manner and to the same extent as other respiratory viruses for which a clinical benefit has been proven. Authors note that clinical data and post market surveillance data show that iota-carrageenan is well-tolerated with very low reported adverse events.

15 preclinical studies support the efficacy of iota-carrageenan for COVID-19:

4 In Silico studies1-4

11 In Vitro studies3,5-14

Important missing comments or errors? Let us know.

1. Rohilla et al., Algae Polysaccharides (Carrageenan and Alginate)—A Treasure-Trove of Antiviral Compounds: An In Silico Approach to Identify Potential Candidates for Inhibition of S1-RBD Spike Protein of SARS-CoV-2, Stresses, doi:10.3390/stresses3030039.mdpi.com, doi.org.

2. Thet, H., The potential of carrageenan for the drug discovery of COVID-19 via molecular docking with angiotensin-converting enzyme 2 (ACE2) and the main protease (Mpro) of SARS-CoV-2, Journal of Bioinformatics and Genomics, doi:10.18454/jbg.2022.18.2.001.journal-biogen.org, doi.org.

3. Alsaidi et al., Griffithsin and Carrageenan Combination Results in Antiviral Synergy against SARS-CoV-1 and 2 in a Pseudoviral Model, Marine Drugs, doi:10.3390/md19080418.mdpi.com, doi.org.

4. Sattari et al., Repositioning Therapeutics for COVID-19: Virtual Screening of the Potent Synthetic and Natural Compounds as SARS-CoV-2 3CLpro Inhibitors, Research Square, doi:10.21203/rs.3.rs-37994/v1.researchsquare.com, doi.org.

5. Yathindranath et al., Lipid Nanoparticle-Based Inhibitors for SARS-CoV-2 Host Cell Infection, International Journal of Nanomedicine, doi:10.2147/IJN.S448005.dovepress.com, doi.org.

6. Setz et al., Iota-Carrageenan Inhibits Replication of the SARS-CoV-2 Variants of Concern Omicron BA.1, BA.2 and BA.5, Nutraceuticals, doi:10.3390/nutraceuticals3030025.mdpi.com, doi.org.

7. Meister et al., Virucidal activity of nasal sprays against severe acute respiratory syndrome coronavirus-2, Journal of Hospital Infection, doi:10.1016/j.jhin.2021.10.019.sciencedirect.com, doi.org.

8. Bovard et al., Iota-carrageenan extracted from red algae is a potent inhibitor of SARS-CoV-2 infection in reconstituted human airway epithelia, Biochemistry and Biophysics Reports, doi:10.1016/j.bbrep.2021.101187.sciencedirect.com, doi.org.

9. Fröba et al., Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta, International Journal of Molecular Sciences, doi:10.3390/ijms222413202.mdpi.com, doi.org.

10. Varese et al., Iota-carrageenan prevents the replication of SARS-CoV-2 on an in vitro respiratory epithelium model, bioRxiv, doi:10.1101/2021.04.27.441512.biorxiv.org, doi.org.

11. Morokutti-Kurz et al., Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro, PLoS ONE, doi:10.1371/journal.pone.0237480.plos.org, doi.org.

12. Song et al., Inhibitory activities of marine sulfated polysaccharides against SARS-CoV-2, Food & Function, doi:10.1039/D0FO02017F.rsc.org, doi.org.

13. Bansal et al., Iota-carrageenan and xylitol inhibit SARS-CoV-2 in Vero cell culture, PLoS ONE, doi:10.1371/journal.pone.0259943.plos.org, doi.org.

14. Morokutti-Kurz (B) et al., Amylmetacresol/2,4-dichlorobenzyl alcohol, hexylresorcinol, or carrageenan lozenges as active treatments for sore throat, International Journal of General Medicine, doi:10.2147/IJGM.S120665.dovepress.com, doi.org.

Morokutti-Kurz et al., 17 Feb 2021, peer-reviewed, 8 authors.

In Vitro studies are an important part of preclinical research, however results may be very different in vivo.

This Paper Iota-carragee..All

Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro

Martina Morokutti-Kurz, Maria Fröba, Philipp Graf, Maximilian Große, Andreas Grassauer, Janina Auth, Ulrich Schubert, Eva Prieschl-Grassauer

PLOS ONE, doi:10.1371/journal.pone.0237480

In the absence of a vaccine and other effective prophylactic or therapeutic countermeasures the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) remains a significant public health threat. Attachment and entry of coronaviruses including SARS-CoV-2 is mainly mediated by the spike glycoprotein. Here, we show that iota-carrageenan can inhibit the cell entry of the SARS-CoV-2 spike pseudotyped lentivirus in a dose dependent manner. SARS-CoV-2 spike pseudotyped lentivirus particles were efficiently neutralized with an IC 50 value of 2.6 μg/ml iota-carrageenan. Experiments with patient isolated wild type SARS-CoV-2 virus showed an inhibition of replication in a similar range. In vitro data on iotacarrageenan against various Rhino-and endemic Coronaviruses showed similar IC 50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction of severity and duration of symptoms of common cold caused by various respiratory viruses. Accordingly, our in vitro data on SARS-CoV-2 spike pseudotyped lentivirus and replication competent SARS-CoV-2 suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections.

Supporting information S1 Author Contributions Conceptualization: Martina Morokutti-Kurz, Andreas Grassauer, Ulrich Schubert, Eva Prieschl-Grassauer. Data curation: Martina Morokutti-Kurz, Maria Fro ¨ba, Philipp Graf, Maximilian Große, Janina Auth, Ulrich Schubert, Eva Prieschl-Grassauer. Formal analysis: Martina Morokutti-Kurz, Maria Fro ¨ba, Philipp Graf, Maximilian Große, Andreas Grassauer, Janina Auth. Funding acquisition: Andreas Grassauer, Ulrich Schubert, Eva Prieschl-Grassauer. Investigation: Maria Fro ¨ba, Philipp Graf, Maximilian Große, Janina Auth. Methodology: Martina Morokutti-Kurz, Maria Fro ¨ba, Janina Auth, Ulrich Schubert. Project administration: Janina Auth, Eva Prieschl-Grassauer. Resources: Andreas Grassauer, Janina Auth, Ulrich Schubert, Eva Prieschl-Grassauer. Software: Eva Prieschl-Grassauer. Supervision: Ulrich Schubert. Validation: Eva Prieschl-Grassauer. Visualization: Eva Prieschl-Grassauer. Writing -original draft: Martina Morokutti-Kurz, Andreas Grassauer, Ulrich Schubert, Eva Prieschl-Grassauer. Writing -review & editing: Martina Morokutti-Kurz, Maria Fro ¨ba, Maximilian Große, Andreas Grassauer, Ulrich Schubert, Eva Prieschl-Grassauer.

References

Corman, Landt, Kaiser, Molenkamp, Meijer et al., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR, Euro Surveill, doi:10.2807/1560-7917.ES.2020.25.3.2000045

Dogan, Kozhaya, Placek, Gunter, Yigit et al., Novel SARS-CoV-2 specific antibody and neutralization assays reveal wide range of humoral immune response during COVID-19, medRxiv, doi:10.1101/2020.07.07.20148106

Eccles, Iota-Carrageenan as an Antiviral Treatment for the Common Cold, The Open Virology Journal

Eccles, Meier, Jawad, Weinmu ¨llner R, Grassauer et al., Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold, Respir Res, doi:10.1186/1465-9921-11-108

Eccles, Winther, Johnston, Robinson, Trampisch et al., Efficacy and safety of iotacarrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial, Respir Res, doi:10.1186/s12931-015-0281-8

Fazekas, Eickhoff, Pruckner, Vollnhofer, Fischmeister et al., Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold, BMC Complement Altern Med, doi:10.1186/1472-6882-12-147

Gates, Responding to Covid-19-A Once-in-a-Century Pandemic, N Engl J Med, doi:10.1056/NEJMp2003762

Grassauer, Weinmu ¨llner R, Meier, Pretsch, Prieschl-Grassauer et al., Iota-Carrageenan is a potent inhibitor of rhinovirus infection, Virol J, doi:10.1186/1743-422X-5-107

Große, Ruetalo, Businger, Rheber, Setz et al., Evidence That Quinine Exhibits Antiviral Activity against SARS-CoV-2 Infection In Vitro, Preprints

Hoffmann, Kleine-Weber, Schroeder, Kru ¨ger, Herrler et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, doi:10.1016/j.cell.2020.02.052

Koenighofer, Lion, Bodenteich, Prieschl-Grassauer, Grassauer et al., Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials, Multidiscip Respir Med, doi:10.1186/2049-6958-9-57

Leibbrandt, Meier, Ko ¨nig-Schuster, Weinmu ¨llner R, Kalthoff et al., Iota-Carrageenan Is a Potent Inhibitor of Influenza A Virus Infection, PLoS One, doi:10.1371/journal.pone.0014320

Long, Tang, Shi, Li, Deng et al., Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections, Nat Med, doi:10.1038/s41591-020-0965-6

Ludwig, Enzenhofer, Schneider, Rauch, Bodenteich et al., Efficacy of a carrageenan nasal spray in patients with common cold: a randomized controlled trial, Respir Res, doi:10.1186/1465-9921-14-124

Mcintosh, Dees, Becker, Kapikian, Chanock, Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease, Proc Natl Acad Sci U.S.A, doi:10.1073/pnas.57.4.933

Morokutti-Kurz, Konig-Schuster, Koller, Graf, Graf et al., The Intranasal Application of Zanamivir and Carrageenan Is Synergistically Active against Influenza A Virus in the Murine Model 4944, PLoS ONE, doi:10.1371/journal.pone.0128794

Perlman, Another Decade, Another Coronavirus, N Engl J Med, doi:10.1056/NEJMe2001126

Reed, Muench, A simple method of estimating fifty percent endpoints, Am J Hyg

Wu, Zhao, Yu, Chen, Song, A new coronavirus associated with human respiratory disease in China, Nature, doi:10.1038/s41586-020-2008-3

Zhu, Zhang, Li, Yang, Song, A Novel Coronavirus from Patients with Pneumonia in China, 2019, N Engl J Med, doi:10.1056/NEJMoa2001017

{ 'indexed': {'date-parts': [[2024, 5, 8]], 'date-time': '2024-05-08T13:53:49Z', 'timestamp': 1715176429581}, 'reference-count': 20, 'publisher': 'Public Library of Science (PLoS)', 'issue': '2', 'license': [ { 'start': { 'date-parts': [[2021, 2, 17]], 'date-time': '2021-02-17T00:00:00Z', 'timestamp': 1613520000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}], 'funder': [ { 'DOI': '10.13039/501100004955', 'name': 'Österreichische Forschungsförderungsgesellschaft', 'doi-asserted-by': 'publisher', 'award': ['880687']}], 'content-domain': {'domain': ['www.plosone.org'], 'crossmark-restriction': False}, 'abstract': 'In the absence of a vaccine and other effective prophylactic or therapeutic ' 'countermeasures the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) ' 'remains a significant public health threat. Attachment and entry of coronaviruses including ' 'SARS-CoV-2 is mainly mediated by the spike glycoprotein. Here, we show that iota-carrageenan ' 'can inhibit the cell entry of the SARS-CoV-2 spike pseudotyped lentivirus in a dose dependent ' 'manner. SARS-CoV-2 spike pseudotyped lentivirus particles were efficiently neutralized with ' 'an IC50 value of 2.6 μg/ml iota-carrageenan. Experiments with patient ' 'isolated wild type SARS-CoV-2 virus showed an inhibition of replication in a similar range. ' 'In vitro data on iota-carrageenan against various Rhino- and endemic Coronaviruses showed ' 'similar IC50 values and translated readily into clinical effectiveness ' 'when a nasal spray containing iota-carrageenan demonstrated a reduction of severity and ' 'duration of symptoms of common cold caused by various respiratory viruses. Accordingly, our ' 'in vitro data on SARS-CoV-2 spike pseudotyped lentivirus and replication competent SARS-CoV-2 ' 'suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or ' 'treatment for SARS-CoV-2 infections.', 'DOI': '10.1371/journal.pone.0237480', 'type': 'journal-article', 'created': {'date-parts': [[2021, 2, 17]], 'date-time': '2021-02-17T18:34:13Z', 'timestamp': 1613586853000}, 'page': 'e0237480', 'update-policy': 'http://dx.doi.org/10.1371/journal.pone.corrections_policy', 'source': 'Crossref', 'is-referenced-by-count': 74, 'title': 'Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro', 'prefix': '10.1371', 'volume': '16', 'author': [ {'given': 'Martina', 'family': 'Morokutti-Kurz', 'sequence': 'first', 'affiliation': []}, {'given': 'Maria', 'family': 'Fröba', 'sequence': 'additional', 'affiliation': []}, {'given': 'Philipp', 'family': 'Graf', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maximilian', 'family': 'Große', 'sequence': 'additional', 'affiliation': []}, {'given': 'Andreas', 'family': 'Grassauer', 'sequence': 'additional', 'affiliation': []}, {'given': 'Janina', 'family': 'Auth', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ulrich', 'family': 'Schubert', 'sequence': 'additional', 'affiliation': []}, {'given': 'Eva', 'family': 'Prieschl-Grassauer', 'sequence': 'additional', 'affiliation': []}], 'member': '340', 'published-online': {'date-parts': [[2021, 2, 17]]}, 'reference': [ { 'key': 'pone.0237480.ref001', 'doi-asserted-by': 'crossref', 'first-page': '727', 'DOI': '10.1056/NEJMoa2001017', 'article-title': 'A Novel Coronavirus from Patients with Pneumonia in China, 2019', 'volume': '382', 'author': 'N Zhu', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': 'pone.0237480.ref002', 'doi-asserted-by': 'crossref', 'first-page': '265', 'DOI': '10.1038/s41586-020-2008-3', 'article-title': 'A new coronavirus associated with human respiratory disease in China', 'volume': '579', 'author': 'F Wu', 'year': '2020', 'journal-title': 'Nature'}, { 'key': 'pone.0237480.ref003', 'doi-asserted-by': 'crossref', 'first-page': '760', 'DOI': '10.1056/NEJMe2001126', 'article-title': 'Another Decade, Another Coronavirus', 'volume': '382', 'author': 'S. Perlman', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': 'pone.0237480.ref004', 'doi-asserted-by': 'crossref', 'first-page': '1677', 'DOI': '10.1056/NEJMp2003762', 'article-title': 'Responding to Covid-19—A Once-in-a-Century Pandemic', 'volume': '382', 'author': 'B. Gates', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': 'pone.0237480.ref005', 'doi-asserted-by': 'crossref', 'first-page': '271', 'DOI': '10.1016/j.cell.2020.02.052', 'article-title': 'SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a ' 'Clinically Proven Protease Inhibitor', 'volume': '181', 'author': 'M Hoffmann', 'year': '2020', 'journal-title': 'Cell'}, { 'issue': '14', 'key': 'pone.0237480.ref006', 'doi-asserted-by': 'crossref', 'first-page': '9', 'DOI': '10.2174/1874357902014010009', 'article-title': 'Iota-Carrageenan as an Antiviral Treatment for the Common Cold', 'volume': '2020', 'author': 'R. Eccles', 'year': '2020', 'journal-title': 'The Open Virology Journal'}, { 'key': 'pone.0237480.ref007', 'doi-asserted-by': 'crossref', 'DOI': '10.1186/1743-422X-5-107', 'article-title': 'Iota-Carrageenan is a potent inhibitor of rhinovirus infection', 'volume': '5', 'author': 'A Grassauer', 'year': '2008', 'journal-title': 'Virol J'}, { 'key': 'pone.0237480.ref008', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pone.0014320', 'article-title': 'Iota-Carrageenan Is a Potent Inhibitor of Influenza A Virus Infection', 'volume': '5', 'author': 'A Leibbrandt', 'year': '2010', 'journal-title': 'PLoS One'}, { 'key': 'pone.0237480.ref009', 'doi-asserted-by': 'crossref', 'first-page': 'e0128794', 'DOI': '10.1371/journal.pone.0128794', 'article-title': 'The Intranasal Application of Zanamivir and Carrageenan Is ' 'Synergistically Active against Influenza A Virus in the Murine Model ' '4944', 'volume': '10', 'author': 'M Morokutti-Kurz', 'year': '2015', 'journal-title': 'PLoS ONE'}, { 'key': 'pone.0237480.ref010', 'doi-asserted-by': 'crossref', 'first-page': '108', 'DOI': '10.1186/1465-9921-11-108', 'article-title': 'Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a ' 'randomized, double-blind, placebo-controlled exploratory study in ' 'volunteers with early symptoms of the common cold', 'volume': '11', 'author': 'R Eccles', 'year': '2010', 'journal-title': 'Respir Res'}, { 'key': 'pone.0237480.ref011', 'doi-asserted-by': 'crossref', 'first-page': '147', 'DOI': '10.1186/1472-6882-12-147', 'article-title': 'Lessons learned from a double-blind randomised placebo-controlled study ' 'with a iota-carrageenan nasal spray as medical device in children with ' 'acute symptoms of common cold', 'volume': '12', 'author': 'T Fazekas', 'year': '2012', 'journal-title': 'BMC Complement Altern Med'}, { 'key': 'pone.0237480.ref012', 'doi-asserted-by': 'crossref', 'first-page': '57', 'DOI': '10.1186/2049-6958-9-57', 'article-title': 'Carrageenan nasal spray in virus confirmed common cold: individual ' 'patient data analysis of two randomized controlled trials', 'volume': '9', 'author': 'M Koenighofer', 'year': '2014', 'journal-title': 'Multidiscip Respir Med'}, { 'key': 'pone.0237480.ref013', 'doi-asserted-by': 'crossref', 'first-page': '124', 'DOI': '10.1186/1465-9921-14-124', 'article-title': 'Efficacy of a carrageenan nasal spray in patients with common cold: a ' 'randomized controlled trial', 'volume': '14', 'author': 'M Ludwig', 'year': '2013', 'journal-title': 'Respir Res'}, { 'key': 'pone.0237480.ref014', 'doi-asserted-by': 'crossref', 'first-page': '121', 'DOI': '10.1186/s12931-015-0281-8', 'article-title': 'Efficacy and safety of iota-carrageenan nasal spray versus placebo in ' 'early treatment of the common cold in adults: the ICICC trial', 'volume': '16', 'author': 'R Eccles', 'year': '2015', 'journal-title': 'Respir Res'}, { 'key': 'pone.0237480.ref015', 'first-page': '2020070102', 'article-title': 'Evidence That Quinine Exhibits Antiviral Activity against SARS-CoV-2 ' 'Infection In Vitro', 'author': 'M Große', 'year': '2020', 'journal-title': 'Preprints'}, { 'key': 'pone.0237480.ref016', 'first-page': '493', 'article-title': 'A simple method of estimating fifty percent endpoints', 'author': 'LJ Reed', 'year': '1938', 'journal-title': 'Am J Hyg'}, { 'key': 'pone.0237480.ref017', 'doi-asserted-by': 'crossref', 'DOI': '10.2807/1560-7917.ES.2020.25.3.2000045', 'article-title': 'Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR', 'volume': '25', 'author': 'VM Corman', 'year': '2020', 'journal-title': 'Euro Surveill'}, { 'key': 'pone.0237480.ref018', 'doi-asserted-by': 'crossref', 'first-page': '933', 'DOI': '10.1073/pnas.57.4.933', 'article-title': 'Recovery in tracheal organ cultures of novel viruses from patients with ' 'respiratory disease', 'volume': '57', 'author': 'K McIntosh', 'year': '1967', 'journal-title': 'Proc Natl Acad Sci U.S.A'}, { 'key': 'pone.0237480.ref019', 'article-title': 'Clinical and immunological assessment of asymptomatic SARS-CoV-2 ' 'infections', 'author': 'Q-X Long', 'year': '2020', 'journal-title': 'Nat Med'}, { 'key': 'pone.0237480.ref020', 'article-title': 'Novel SARS-CoV-2 specific antibody and neutralization assays reveal ' 'wide range of humoral immune response during COVID-19', 'author': 'M Dogan', 'year': '2020', 'journal-title': 'medRxiv'}], 'container-title': 'PLOS ONE', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://dx.plos.org/10.1371/journal.pone.0237480', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 2, 17]], 'date-time': '2021-02-17T18:34:39Z', 'timestamp': 1613586879000}, 'score': 1, 'resource': {'primary': {'URL': 'https://dx.plos.org/10.1371/journal.pone.0237480'}}, 'subtitle': [], 'editor': [{'given': 'Stephen J.', 'family': 'Polyak', 'sequence': 'first', 'affiliation': []}], 'short-title': [], 'issued': {'date-parts': [[2021, 2, 17]]}, 'references-count': 20, 'journal-issue': {'issue': '2', 'published-online': {'date-parts': [[2021, 2, 17]]}}, 'URL': 'http://dx.doi.org/10.1371/journal.pone.0237480', 'relation': {}, 'ISSN': ['1932-6203'], 'subject': [], 'container-title-short': 'PLoS ONE', 'published': {'date-parts': [[2021, 2, 17]]}}

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0